Ultimovacs is a pharmaceutical company developing novel immunotherapies against cancer. The lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase.
UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs which require an ongoing T cell response for their mode of action. Ultimovacs is performing a broad clinical development program with clinical trials in Europe and the USA.
Ultimovacs was established in 2011. The company and its proprietary technology is based on pre-clinical and clinical research on immunotherapies conducted at the Oslo University Hospital. The company is privately held, mainly by Norwegian private investors/family offices.
Ultimovacs has started preparations for a potential listing of the company on Oslo Børs (Oslo Stock Exchange) and the aim is to complete the IPO during first half of 2019
The main purpose of the IPO is to ensure financing of operations and core development projects for the following 5 years with intent to file for marketing authorisation of UV1.
Ultimovacs is developing a new type of cancer treatment. We are currently documenting the safety and efficacy. We do not yet have enough data regarding safety or efficacy to use the treatment outside of our clinical trial program.
If you are a cancer patient and wish to participate in a clinical trial, you should discuss this with the physician responsible for your treatment.